|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | No. of studies | No. of experimental group | No. of control group | RR | 95% CI | *p* | Heterogeneity |
| (I2) (%) |
| All-cause AEs (Any grade) | 4 | 1101 | 793 | 1.01 | 1.00-1.02 | 0.07 | 0 |
| All-cause AEs (Grade more than 3) | 5 | 1410 | 1085 | 1.08 | 1.01-1.16 | *0.02* | 0 |
| Treatment-related AEs (Any grade) | 4 | 1101 | 793 | 1.01 | 1.00-1.02 | 0.07 | 0 |
| Treatment-related AEs (Grade more than 3) | 6 | 1842 | 1302 | 0.92 | 0.68-1.25 | 0.60 | 90 |
| Immune-mediated of AEs (Any grade) | 5 | 1795 | 1267 | 2.31 | 1.46-3.65 | *<0.001* | 92 |
| Immune-mediated of AEs (Grade more than 3) | 5 | 1795 | 1267 | 2.48 | 1.45-4.23 | *<0.001* | 29 |
| AEs leading to treatment discontinuation | 4 | 971 | 729 | 1.49 | 0.80-2.77 | 0.21 | 76 |

**Supplementary Table 2.** Subgroup analysis of the overall AEs of of unresectable locally advanced or metastatic TNBC with PD-1/PD-L1 inhibitor based immunotherapy combined with chemotherapy, versus other treatments.

PD-1/PD-L1: PD-1/PD-L1: programmed cell death protein 1/programmed cell death 1 ligand 1; AEs: adverse events; RR: risk ratio; Cl: confidence interval